Multiparametric MRI (mpMRI) provides a high-accuracy, non-invasive method for distinguishing between luminal and non-luminal invasive ductal carcinoma (IDC) subtypes, according to a study published in Clinical Radiology. Researchers achieved an area under the curve (AUC) of 0.92, suggesting that specific imaging biomarkers could eventually supplement histopathology to guide personalized breast cancer treatment.
Predicting Breast Cancer Subtypes Through Imaging
Distinguishing between breast cancer subtypes—specifically luminal versus non-luminal—is essential for determining treatment paths. Luminal cancers (A and B) and non-luminal types like HER2-enriched and triple-negative cancers are different subtypes. A prospective study of 102 patients, led by S. Mohakud and colleagues, evaluated whether 3T multiparametric MRI could reliably classify these tumors before treatment.
The research protocol integrated multiple imaging modalities, including T1- and T2-weighted imaging, subtraction imaging, dynamic contrast-enhanced (DCE) MRI, diffusion-weighted imaging (DWI), and MR spectroscopy (MRS). By analyzing these parameters, the team identified distinct visual and quantitative markers for each subtype.
Did you know?
Non-luminal tumors frequently display “rim enhancement” and perilesional edema, whereas luminal tumors are more likely to present as irregular masses with spiculated margins.
Key Imaging Biomarkers for Diagnosis
The study found that non-luminal cancers exhibit specific physiological characteristics detectable via advanced imaging. Patients with non-luminal disease typically demonstrated higher Ktrans values, higher signal enhancement ratios (SER), and lower apparent diffusion coefficient (ADC) values. Furthermore, the presence of a choline peak on MR spectroscopy was more common in this group.
When researchers combined these factors—specifically perilesional edema, low extracellular extravascular volume fraction (Ve), and high SER—they were able to classify tumor subtypes with 87% sensitivity and 86% specificity. These metrics offer a potential “imaging biopsy” that could provide clinicians with immediate insight into tumor biology before invasive procedures are finalized.
Path Toward Clinical Implementation
While the 0.92 AUC score is promising, the authors emphasize that this remains a single-center study. Before mpMRI can be standardized as an adjunct to traditional histopathology, external validation across larger, diverse patient populations is necessary.
If these findings are replicated in multicenter trials, mpMRI could become a standard tool for prognostication. By identifying the subtype non-invasively, clinicians may be better equipped to tailor chemotherapy or targeted therapy regimens from the moment of diagnosis.
Pro Tip:
For clinicians reviewing MRI results, the combination of perilesional edema and specific SER values serves as a strong indicator of non-luminal status, according to the Clinical Radiology findings.
Frequently Asked Questions
Can MRI replace a traditional breast cancer biopsy?
Currently, no. The study describes mpMRI as a “reliable adjunct to histopathology,” meaning it is intended to support, not replace, the definitive diagnosis provided by a biopsy.
What are the primary differences between luminal and non-luminal IDC?
Non-luminal tumors include HER2-enriched and triple-negative cancers. Luminal tumors are categorized as A and B.
Why is external validation required for these findings?
External validation ensures that the imaging markers identified in this specific group of 102 patients hold true across different MRI machines, hospital settings, and patient demographics.
Have questions about the latest in breast cancer imaging technology? Subscribe to our newsletter for updates on the latest clinical research or join the discussion in the comments section below.
Related reading